CP
CLBT icon

Castleview Partners’s Cellebrite CLBT Stock Holding History

Castleview Partners’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,146
Closed -$256K – 937
2024
Q1 		$256K Buy
+23,146
New +$236K 0.14% 155

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Castleview Partners's CLBT Position: Q2 2024 in Review

Castleview Partners sold out of Cellebrite (CLBT) in Q2 2024, closing a stake of 23,146 shares — an estimated $256K sold.

Castleview Partners first reported a position in CLBT in Q1 2024 and held it in 1 quarter. The position peaked at $256K in Q1 2024. 148 funds tracked by Wall St. Rank hold CLBT as of Q2 2024.

  • Castleview Partners reported no remaining Cellebrite position as of Q2 2024 after selling out during the quarter.
  • Castleview Partners sold 23,146 Cellebrite shares in Q2 2024, an estimated $256K.
  • Castleview Partners first reported a position in Cellebrite in Q1 2024 and held it in 1 quarter.
  • Castleview Partners's Cellebrite position peaked at $256K in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Cellebrite as of Q2 2024.

Based on Castleview Partners's 13F filing for Q2 2024, filed 31 Jul 2024.